Biotechnology Newly Diagnosed Cervical Cancer Patients – Merck’s Blockbuster Drug Keytruda Plus Chemoradiotherapy Improves Overall Survival – Merck & Co (NYSE:MRK) Read more
Biotechnology Pfizer-Acquired Seagen’s Adcetris Combo Therapy Extends Overall Survival Versus Placebo In Patients With Most Common Type Of Lymphoma – Pfizer (NYSE:PFE) Read more
Biotechnology Merck’s Multi-Billion Cancer Drug Keytruda Improves Disease-Free Survival In Advanced Bladder Cancer After Surgery, Data Shows – Merck & Co (NYSE:MRK) Read more